|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Dental Medicine / Faculty of Dental Medicine >
Peer-reviewed Journal Articles, etc >
Ethyl loflazepate as a treatment for patients with idiopathic and psychogenic taste disorder
| Title: | Ethyl loflazepate as a treatment for patients with idiopathic and psychogenic taste disorder |
| Authors: | Sakata, Ken-ichiro Browse this author →KAKEN DB | | Hato, Hiroyuki Browse this author | | Sato, Jun Browse this author →KAKEN DB | | Iori, Takashi Browse this author | | Ohga, Noritaka Browse this author →KAKEN DB | | Watanabe, Haruhisa Browse this author | | Yamazaki, Yutaka Browse this author →KAKEN DB | | Kitagawa, Yoshimasa Browse this author →KAKEN DB |
| Keywords: | Ethyl loflazepate | | Idiopathic taste disorder | | Psychogenic taste disorder |
| Issue Date: | 8-Aug-2022 |
| Publisher: | BioMed Central |
| Journal Title: | BioPsychoSocial Medicine |
| Volume: | 16 |
| Issue: | 1 |
| Start Page: | 16 |
| Publisher DOI: | 10.1186/s13030-022-00246-1 |
| PMID: | 35941665 |
| Abstract: | Background Ethyl loflazepate (EL) is a benzodiazepine derivative that has been reported to activate the gustatory cortex. Our department routinely uses EL as a first-line treatment for idiopathic and psychogenic taste disorders, although little has been reported in the literature with respect to patient outcomes, so we conducted a retrospective study examining its safety and efficacy. Methods Between 2008 and 2020, 49 patients (14 males and 35 females; mean age, 62.1 years) were diagnosed with taste disorders and received EL as their only treatment for > 14 days. Severity of taste disorder was evaluated using the paper disc method by Sakai et al., and treatment efficacy was evaluated using the Visual Analog Scale, wherein patients gave subjective ratings for their symptoms (reductions by > 50% after administration of EL for 4 weeks were defined as improvements). Results Results showed that the improvement rates for patients with idiopathic and psychogenic taste disorders were 55 and 70%, respectively. Additionally, the majority (78%) improved within 2 weeks, and side effects were mild (seven cases with drowsiness and one case with dizziness). Conclusions We conclude that EL is an appropriate first-line medication for patients with idiopathic and psychogenic taste disorders. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/86765 |
| Appears in Collections: | 歯学院・歯学研究院 (Graduate School of Dental Medicine / Faculty of Dental Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
